NEXTURNBIOSCIENCE Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 28.48 million compared to KRW 29.38 million a year ago. Net income was KRW 4,848.43 million compared to net loss of KRW 6,174.53 million a year ago. Basic earnings per share from continuing operations was KRW 750 compared to basic loss per share from continuing operations of KRW 965 a year ago. Diluted earnings per share from continuing operations was KRW 350 compared to diluted loss per share from continuing operations of KRW 965 a year ago. Basic earnings per share was KRW 750 compared to basic loss per share of KRW 965 a year ago. Diluted earnings per share was KRW 350.
For the six months, sales was KRW 62.3 million compared to KRW 57.71 million a year ago. Net income was KRW 3,295.27 million compared to net loss of KRW 4,391.57 million a year ago. Basic earnings per share from continuing operations was KRW 510 compared to basic loss per share from continuing operations of KRW 685 a year ago. Diluted earnings per share from continuing operations was KRW 270 compared to diluted loss per share from continuing operations of KRW 685 a year ago. Basic earnings per share was KRW 510 compared to basic loss per share of KRW 685 a year ago. Diluted earnings per share was KRW 270.